

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
直江知樹	がん生物学イラストレイテッド	鍬塚八千代 直江知樹	イマチニブと耐性克服	羊土社	東京	2011	202-207
薄井紀子	Gemutuzumab/ozogamicin	弦間昭彦編	分子標的治療薬の副作用マネジメント	南江堂	東京	2011	110-117
臼杵憲祐	免疫抑制療法	小澤敬也	最新医学別冊「新しい診断と治療のABC 72 再生不良性貧血」	最新医学社	大阪	2011	108-119
臼杵憲祐	再生不良性貧血	山口徹、北原光夫、福井次矢	今日の治療指針2012年版	医学書院	東京	2012	567-569
臼杵憲祐	G-CSFを投与したAMLの一例	溝口秀昭、齋藤英彦、吉田彌太郎、小澤敬也	私のこの一枚標本に学ぶ血液疾患症例	医薬ジャーナル社	大阪	2012	94-96
松村到	ニロチニブ	西田俊朗、大津敦、土井俊彦	血管新生阻害薬ベストマネジメント	金原出版	東京	2011	153-155
松村到	慢性骨髄性白血病	山口徹、北原光夫、福井次矢	今日の治療指針2012年版	医学書院	東京	2012	582-584
直江知樹	概念と分類	大野竜三	急性白血病(改訂第2版)	最新医学別冊	日本	2012	13-23
薄井紀子	白血病の化学療法	有吉 寛	癌化学療法ハンドブック2012	メディカルレビュー社	日本	2012	482-509
臼杵憲祐	白血球減少症	横田千津子、池田宇一、大越教夫	薬局増刊号、病気と薬バイブル2012	南山堂	日本	2012	1180-1186

半下石明、臼杵憲祐	緩和ケア	木崎昌弘	多発性骨髄腫治療マニュアル	南江堂	日本	2012	271-278
臼杵憲祐	急性白血病治療時の顆粒球コロニー刺激因子の使い方		最新医学別冊「新しい診断と治療のABC 36急性白血病（改訂第2版）」	最新医学社	日本	2012	206-216
臼杵憲祐	骨髓不全症に対するG-CSFの適応と至適投与	金倉議、木崎昌弘、鈴木律朗、神田善伸	EBM 血液疾患の治療 2013-2014	中外医学社	日本	2012	474-483
伊藤良和、大屋敷一馬	高齢者急性白血病の治療（急性骨髓性白血病を中心）	大野竜三	新しい診断と治療のABC（最新医学別冊）36 急性白血病（改訂第2版）	最新医学社	日本	2012	147-154
平瀬主税、松村 到	慢性骨髓性白血病 慢性期の慢性骨髓性白血病の病因・病態		日本臨床 70巻 増刊号 2号	日本臨床社	日本	2012	293-297
田中宏和、松村 到	イマチニブ抵抗性・不耐容の慢性期CMLに対する治療方針	金倉 譲他	EBM血液疾患の治療 2013-2014	中外医学社	日本	2012	168-172
松村 到	慢性骨髓性白血病の診断と治療		日本検査血液学会誌	日本検査医学会	日本	2013	1-8
大西一功	抗腫瘍薬	門脇 孝, 永井 良三	カラー版内科学	西村書店	東京	2012	192-195
大西一功	急性骨髓性白血病	山口 徹	今日の治療指針 2013	医学書院	東京	2013	602-605
大西一功	白血病	日本血液学会	造血期細胞治療診療ガイドライン2013年版	金原出版	東京	2013	1-129
薄井紀子	成人急性骨髓性白血病の治療.		日本内科学会雑誌	日本内科学会	日本	2013	102(7) : 1687-1695
大西一功	急性リンパ性白血病	矢崎義雄	朝倉内科学	朝倉書店	東京	2013	2006-2008
麻生範雄、品川克至、藤田浩之	急性前骨髓球性白血病	日本血液学会	造血器腫瘍診療ガイドライン	金原出版	東京	2013	32-52

臼杵憲祐	治療コンセプト	直江知樹	インフォームドコンセントのための図説シリーズ 白血病・骨髄異形成症候群	医薬ジャーナル社	日本	2013	24-27
臼杵憲祐	骨髓不全（再生不良性貧血、骨髓異形成症候群）	東條有伸	G-CSFの基礎と臨床	医薬ジャーナル社	日本	2013	138-153
臼杵憲祐	再生不良性貧血	浦部晶夫他	今日の処方改訂第5版	南江堂	日本	2013	480-484
臼杵憲祐	溶血性貧血	浦部晶夫他	今日の処方改訂第5版	南江堂	日本	2013	485-489
臼杵憲祐	骨髓異形成症候群	浦部晶夫他	今日の処方改訂第5版	南江堂	日本	2013	496-500
臼杵憲祐	急性白血病	浦部晶夫他	今日の処方改訂第5版	南江堂	日本	2013	501-506
臼杵憲祐	慢性骨髓性白血病	浦部晶夫他	今日の処方改訂第5版	南江堂	日本	2013	507-509
臼杵憲祐	二次性（症候性）貧血	木崎昌弘	カラーテキスト血液学	中外医学社	日本	2013	322-325
臼杵憲祐	巨赤芽球性貧血	木崎昌弘	カラーテキスト血液学	中外医学社	日本	2013	326-331
臼杵憲祐	高リスク骨髓異形成症候群	直江知樹、小澤敬也、中尾眞二	血液疾患最新の治療 2014-2016	南江堂	日本	2014	153-156
臼杵憲祐	エルトロンボパグによる再生不良性貧血の治療	高久史磨、小澤敬也、坂田洋一、金倉譲、小島勢二	Annual review of blood 2014	中外医学社	日本	2014	.59-66
伊藤良和 大屋敷一馬	高齢者白血病	直江知樹	インフォームドコンセントのための図説シリーズ 白血病 / 骨髄異形成症候群	医薬ジャーナル社	大阪	2013	pp86-91
今井陽俊	どんなときに移植を選ぶか？	直江知樹	インフォームドコンセントのための図説シリーズ	医薬ジャーナル社	日本	2013	54-61

今井陽俊	急性リンパ性白血病	直江知樹、小澤敬也、中尾眞二	血液疾患 最新の治療2014-2016	南江堂	日本	2014	157-160
今井陽俊	急性リンパ性白血病（成人）	直江知樹、堀部敬三	チーム医療のための血液がんの標準的化学療法	メディカル・サイエンス・インターナショナル	日本	2013	295-314
平瀬主税、田中宏和、松村 到	第3世代チロシンキナーゼ阻害薬ポナチニブの有効性と安全性	高久文磨 小澤敬也 坂田洋一 金倉 譲 小島勢二	Annual Review of Blood	中外医学社	東京	2014	110-116
田中宏和、松村 到	初発慢性期の慢性骨髄性白血病	松村 到、金倉 譲	ここまできた白血病/MDS治療	中外医学社	東京	2013	250-259
松村 到	慢性骨髄性白血病	矢崎義雄	朝倉内科学第10版	朝倉書店	東京	2013	739-743

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Usui N, Takeshita A, Nakaseko C, Duzumab ozogamicin in obashi N, Fujita H, Kiyoi H, Kobayashi Y, Sakura T, Yahagi Y, Shigeno K, Ohwada C, Miyazaki Y, Ohtake S, Miyawaki S, Naoue T, Ohnishi K; for the Japan Adult Leukemia Study Group	Phase I trial of gemtuzumab ozogamicin in intensive combination chemotherapy for relapsed or refractory adult acute myeloid leukemia(AML):Japan Adult Leukemia Study Group (JALSG)-AML206 study	Cancer Science	102 ( 7 )	1358-1365	2011
Dobashi N, Usui N, Yano S, Yahagi Y, Takei Y, Sugiyama K, Takahara S, Ogasawara Y, Yamaguchi Y, Saito T, Yokoyama H, Aiba K.	Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institution experience.	Jpn J Clin Oncol	41	820-824	2011
Ono T, Takeshita A, Iwanaga M, Aso u N, Naoe T, Ohnishi R.	Impact of additional chromosomal abnormalities in patients with acute promyelocytic leukemia: 10-year results of the Japan Adult Leukemia Study Group APL97 study. Haematologica	Haematologica	96	174-176	2011
Kako S, Morita S, Sakamaki H, Ogawa H, Fukuda T, Taiji et al., Kanamori H, Onizuka M, Iwato K, Suzuki R, Atsuta Y, Kyoto T, Sakura T, Jinna I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y.	A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor.	Leukemia	25	259-265	2011
Uenogawa K, Hatta Y, Arima N, Hayakawa S, Sawada U, Aizawa S, Yamamoto T, Takeuchi J.	Azacitidine induces demethylation of p16INK4a and inhibits growth in adult T-cell leukemia/lymphoma.	Int J Mol Med	28	835-839	2011

Usuki K, Tojo A, Maeda Y, Kobayashi F, Ito Y, Matsuda A, Ose patients with imatinib-resistant or -inert Ph+ CML or rT, Tanaka H, Miyaelapsed/refractory Phmura K, Miyazaki Y, Okamoto S, Ori tani K, Okada M, Usui N, Nagai T, Amagasaki T, Wana jo A, Naoe T.	Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -inert Ph+ CML or rT, Tanaka H, Miyaelapsed/refractory Phmura K, Miyazaki Y, Okamoto S, Ori tani K, Okada M, Usui N, Nagai T, Amagasaki T, Wana jo A, Naoe T.	Int J Hematol.	95	1026-1029	2012
Kobayashi Y, Saka maki H, Fujisawa S, Ando K, Yamamote K, Okada M, Itohizawa K, Nagai T, Miyawaki S, Moto toji T, Usui N, Iida S, Taniwaki M, Uoshima N, Seriu T, Ohno R.	Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis	Int J Hematol.	93	745-749	2011
Kobayashi Y.	Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.	Jpn J Clin Oncol	41	157-164	2011
Tominaga-Sato S, Tsushima H, Ando K, Itonaga H, Imaizumi Y, Imanishi D, Iwanaga M, Tayama T, Yoshida S, Hata T, Moriuchi Y, Kuriyama K, Mano H, Tomonaga M, Miyazaki Y	Expression of myeloperoxidase and gene mutations in AML patient with normal karyotype: double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts	Int J Hematol	94 (1)	81-89	2011
Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Moriuchi S, Kamihira S, Tomonaga M, Miyazaki Y	Successful treatment of a chronic-phase T315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa	Int J Hematol	95 (2)	209-213	2012

Tsushima H, Iwanga M, Miyazaki Y	Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes	Int J Hematol	95(3)	232-238	2012
Ohnishi K, Nakaseko C, Takeuchi J, Fujisawa S, Nagahashi T, Yamazaki H, Tauchi T, Imai K, Mori N, Yagasaki F, Maeda Y, Usui N, Miyazaki Y, Miyamura K, Kiyoi H, Otake S, Naoe T.	Long-term outcome of imatinib therapy, with assessment of its dosage and blood levels, for chronic myelogenous leukemia.	Cancer Sci	j.1349-7006	2012	
Terakura S, Atsuta Y, Sawa M, Ohashiki H, Kato T, Nishiwaki S, Imahashi N, Yasuda T, Murata M, Miyamura K, Suzuki R, Naoe T, Ito T, Morishita Y; for the Nogoya Blood and Marrow Transplantation Group.	A prospective dose-finding trial using a modified continual re-assessment method for optimization of fludarabine plus melphalan conditioning for marrow transplantation from unrelated donors for the Nogoya Blood and Marrow Transplantation Group.	Ann Oncol	22	1865-1871	2011
Atsuta Y., Morishima Y., Suzuki R., Nagamura-Inoue T., Taniguchi S., Takahashi S., Kai S., Sakamaki H., Kouzai Y., Kubo H., Kobayashi N., Fukuda T., Azuma H., Takanashi M., Mori T., Tsuchida M., Kawase T., Kawa K., Kodera Y. and Kato S. for the Japan Marrow Donor Program and the Japan Cord Blood Bank Network	Comparison of unrelated cord blood transplantation and HLA mismatched unrelated bone marrow transplantation for adults with leukemia.	Biol Blood Marrow Transplant	18	780-787	2012

Kanda J., Saji H., Fukuda T., Koon bayashi T., Miyam ura K., Eto T., Kurokawa M., Kanamori H., Mori T., Hidaka M., Iwato K., Yoshida T., akamaki H., Tanaka a J., Kawa M., Morishima Y., Suzuki R., Atsuta Y. and Kanda Y.	Related transplantation with HLA 1-antigen mismatch in the graft-versus-host direct interaction and HLA 8/8-allele matched unrelated transplantation: A nationwide retrospective study.	Blood	19	2409-2416	2012
Masaru Shibayama, Sachiko Ezoe, Kenji Matsui, Masahiro Tokunaga, Natsuko Fujita, Yuri Saito, Takayuki Takahashi, Masayuki Hinohara, Itaru Matsumura, Yuzuru Kanakura	Predictability of the response to tyrosine kinase inhibitors via <i>in vitro</i> analysis of Bcr-Abl phosphorylation	Leukemia Research	35	1205-1211	2011
Satoh Y, Matsumura I, Tanaka H, Harada H, Matsui K, Shiba M,	C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.	Leukemia.	26	303-311	2011
Ohyashiki K, Katagiri SI, Tauchi T, Ohyashiki JH, Maeda Y, Matsumura I, Kyo TI.	Increased natural killer cells and decreased CD3(+) CD8(+) CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.	Br J Haematol	157	254-256	2011
薄井紀子	再発・治療抵抗性成人AMLに対するアプローチ	血液内科	63 ( 5 )	513-519	2011
臼杵憲祐	MPNのリスク分類（予後因子）	最新医学	66	2502-2511	2011

Nakamura S, Nagata Y, Tan L, Takekura T, Shibata K, Fujie M, Fujisawa S, Tanaka Y, Tomoda M, Makita R, Tsuchiya K, Yamada M, Yamaoka M, Yamashita J, Ohnishi K, Yamashita M.	Transcriptional repression of Cdc25B by EGR5 inhibits the proliferation of leukemic progenitor cells through NF-YB and p300 in acute myeloid leukemia.	PLoS One.	6(11)	e28011	2011
Nakamura S, Takekura T, Tan L, Nagata Y, Yokota D, Hirano I, Shigeno K, Shibata K, Fujisawa S, Ohnishi K.	Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.	Carcinogenesis	32(12)	1758-72	2011
Ono T, Miyawaki S, Kimura F, Kanamori H, Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R, Ohnishi K.	BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive acute leukemia by use of the PCR-Invader assay.	Leuk Res.	35(5)	598-603	2011
Nakamura S, Yokota D, Tan L, Nagata Y, Takemura T, Hirano I, Shigeno K, Shibata K, Fujisawa S, Ohnishi K.	Down-regulation of Thrin 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.	Int J Cancer.	130(5)	1046-59	2012
Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R.	Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.	Leukemia.	25	41-7.	2011

Ishiyama K, Takami A, Kanda Y, Nakao S, Hidaka M, Miwa T, Naoe T, Taniguchi S, Kawakubo K, Nagamura T, Tabuchi K, Atsuta Y, Sakamaki H.	Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant.	Leukemia.	6	1416-9.	2012
Kuwatsuka Y, Kohno A, Terakura S, Saito S, Shimada K, Yasuda T, Inamoto Y, Miyamura K, Sawa M, Murata M, Karasuno T, Taniguchi S, Nagafuchi K, Atsuta Y, Suzuki R, Fukumoto M, Naoe T, Morishita Y; the Nagoya Blood and Marrow Transplantation Group.	Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy.	Cancer Sci.	103(9)	1688-1694.	2012
Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Tsuzuki M, Horikawa K, Matsuda M, Shingawa K, Monma F, Otake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T.	Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia.	Cancer Science	103(11)	1974-1978	2012
Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Otake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N.	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.	Blood	121 ( 16 )	3095-3102	2013
Iriyama N, Yoshinaga Y, Yuan B, Horikoshi A, Hirabayashi Y, Hatta Y, Toyoda H, Takeuchi J	Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient.	J Hematol Oncol	24;5:1	doi:10.1186/1756-8722-5-1.	2012

Yanada M, Kurosawa S, Yamaguchi T, Yamashita T, Moriuchi Y, Ago H, Takeuchi J, Nakamadue H, Taguchi J, Sogeneic akura T, Takamatsu Y, Waki F, Yokoyama H, Watanabe M, Emi N, Fukuda T	Prognosis of acute myeloid leukemia harboring monosomal karyotype in patients treated with or without allogeneic hematopoietic cell transplantation after achieving complete remission.	Haematologica	97(6)	915-918	2012
Iriyama N, Yuan B, Hatta Y, Horikoshi A, Yoshino Y, Toyoda H, Aizawa S, Takeuchi J	Granulocyte colony-stimulating factor potentiates differentiation induction by all-trans retinoic acid and arsenic trioxide and enhances arsenic uptake in the acute promyelocytic leukemia cell line HT93A.	Oncol Rep	28(5)	1875-1882	2012
Kako S, Morita S, Sakamaki H, Iida H, Kurokawa M, Miyamura K, Kanamori H, Hara M, Kobayashi N, Morishima Y, Kawa T, Sakura T, Jinmai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y.	The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis.	Bone marrow Transplantation		In press	2013
Usuki K, Kurosawa S, Uchida N, Yakoushi K, Waki F, Matsuishi E, Kagawa K, Furukawa T, Maeda Y, Shimoji T, Maeno Y, Yano S, Fujishima N, Takamatsu Y, Eto T, Hidaka M, Matsuoka H, Fukuda T.	Comparison of Autologous Hematopoietic Cell Transplantation and Chemotherapy as Postremission Treatment in Non-M3 Acute Myeloid Leukemia in First Complete Remission.	Clin Lymphoma Myeloma Leuk	12	444-451	2012

Hiramoto N, Kobayashi Y, Nomoto J, Maruyama D, Watanabe T, Furuta K, Take da K, Chuman H, Yagyu S, Hosoi H, Tobinai K.	Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma.	Jpn J Clin Oncol	43(4)	417-421	2012
Nomoto J, Hiramatsu N, Kato M, Sana da M, Maeshima M, Taniguchi H, Hosoda F, Munakata W, Sekiguchi N, Maruyama D, Watanabe T, Nakagama H, Takeuchi K, Tobinai K, Ogawa S, Kobayashi Y.	Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma.	BMC Cancer.	12	457	2012
Munakata W, Nomoto J, Takahashi N, Taniguchi H, Mae shima AM, Asamuram H, Tanosaki R, Feike Y, Fukuda T, Tobinai K, Kobayashi Y.	Carcinoma of donor origin after allogeneic peripheral blood stem cell transplantation.	Am J Surg Pathol	36 (9)	1376-1384	2012
Ando K, Tsushima H, Matsuo E, Horio K, Tominaga-Sat o K, Imanaga-Sat o S, Imanishi D, Imaizumi Y, Iwana ga M, Itonaga H, Yoshida S, Hata T, Moriuchi R, Kind yoi H, Nimer S, Naoe H, Naonaga T, To monaga M, Miyazaki Y	Mutations in the nuclear phosphoprotein, nucleophosmin, promote the expression of the oncogenic transcript factor MEF/ELF4 in leukemia cells and potentiates transformation.	J Biol Chem	288	9457-9467	2013

Ueda Y, Mizutani C, Nannya Y, Kuroki M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F	Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndrome	Leuk Lymphoma	54 (7)	1450-1458	2013
Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fontsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D	Revised international prognostic scoring system for myelodysplastic syndromes	Blood	120(12)	2454-2465	2012

Ishida T, Hishizawa M, Kato K, Taniguchi R, Fukuda T, Taniguchi S, Eto T, Takatsuka Y, Miyazaki Y, Moriuchi Y, Hidaka M, Akashi K, Uike N, Sakamaki H, Morishima Y, Kato K, Suzuki R, Nishiyama T, Utsunomiya A	Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study	Blood	120(8)	1734-1741	2012
Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, Tanosaki R, Kawano F, Miyazaki Y, Masuda M, Nagafuchi K, Hara M, Takizawa M, Kai S, Atsuta Y, Suzuki R, Kawase T, Matsuo K, Nagamura-Inoue T, Kato S, Sakamaki H, Morishima Y, Okamura J, Ichinohe T, Uchiyama T	Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study	Blood	119(9)	2141-2148	2012
Oki Y, Kondo Y, Yamamoto K, Ogura M, Kasai M, Kobayashi Y, Watanabe T, Uike N, Ohyashiki K, Okamoto S, Ohnishi K, Tomita A, Miyazaki Y, Tohyama K, Mukai HY, Hotta T, Tomonaga M	Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multicenter study in Japan	Cancer Sci	103(10)	1839-1847	2012
Itonaga H, Tsushima H, Hata T, Matsumoto E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Morimoto S, Kamihira S, Tomonaga M, Miyazaki Y	Successful treatment of a chronic-phase T315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa	Int J Hematol	95(2)	209-213	2012

Tsushima H, Iwanga M, Miyazaki Y	Late effect of Atomic bomb radiation on myeloid disorders: leukemia and myelodysplastic syndromes	Int J Hematol	95 ( 3 )	232-238	2012
Wakita A, Otake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kudo K, Kimura Y, Tsuchiya A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R	Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during consolidation after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study	Int J Hematol	96(1)	84-93	2012
Atsuta Y, Kanda J, Takanashi M, Morishima Y, Taniguchi S, Takahashi S, Ogawa H, Ohnishi K, Ohno Y, Onishi Y, Aotsuka N, Nagamura-Inoue T, Kato K, Kanda Y.	Different effects of HLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.	Haematologica		In press	2013
Yasuda T, Suzuki R, Ishikawa Y, Terakura S, Inamoto Y, Yanada M, Nagai H, Ozawa Y, Eki K, Atsuta Y, Emi N, Naoe T.	Randomized controlled trial comparing ciprofloxacin and ceftazidime in febrile neutropenic patients with hematological malignancies.	J Infect Dis.		In press	2013
Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kobayashi N, Fukukuda T, Azuma H, Takanashi M, Mori T, Tsuchida M, Kawase T, Kawa K, Kodera Y, Kato S. for the Japan Marrow Donor Program and the Japan Cord Blood Bank Network	Comparison of unrelated cord blood transplantation and HLA mismatched unrelated bone marrow transplantation for adults with leukemia.	Biol Blood Marrow Transplant	18	780-787	2012

Ito Y, Wakita A, Takada S, Mihara M, Gotoh M, Ohyaishi K, Ohtake S, Miyawaki S, Ohnishi K, Naoe T.	Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study.	Int J Hematol	96(4)	485-91	2012
Matsui K, Ezoe S, Oritani K, Shiba ta M, Tokunaga M, Fujita N, Tanimura A, Sudo T, Tanaka H, Matsumura I, Kanakura Y.	NAD-dependent histone deacetylase, SIRT1, plays essential roles in the maintenance of hematopoietic stem cells.	Biochem Biophys Res Commun.	418 (4)	811-817	2012
Suzuki M, Tanaka H, Tanimura A, Tanyabe K, Oe N, Rai S, Kon S, Fukumoto M, Takei K, Abe T, Matsumura I, Kanakura Y, Watanabe T	The Clathrin assembly Protein PICALM is Required for Erythroid Maturation and Transferrin Internalization in Mice	PLoS ONE	7(2)	e31854	2012
Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K, Shibata M, Mizuki M, Nakamura Y.	C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells.	Leukemia	26(2)	303-311	2012
Mizuta S, Matsuo K, Maeda T, Yujiri i T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Takada S, Yokota A, Takatsuka Y, Tamaki S, Imai K, Moriochi Y, Miyazaki Y, Ohtake S, Ohnishi K, Naoe T.	Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL.	Blood Cancer J	2	e72	2012
薄井紀子	AMLに対する高用量daunorubicin	腫瘍内科	9	163-170	2012

薄井紀子	急性骨髓性白血病(AML)に対するgemtuzumab ozogamicinの臨床的有用性に関する最近の考え方	血液内科	65	245-253	2012
臼杵憲祐	MDSに対する支持療法	血液内科	65	376-382	2012
Ohyashiki K, Kata giri S, Tauchi T, Ohyashiki JH, Maed eda Y, Matsumura I, Kyo T.	Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.	Br J Haematol	157(2)	254-256	2012
Kako S, Morita S, Sakamaki H, Iida H, Kurokawa M, Mi yamura K, Kanamori H, Hara M, Kobayashi N, Morishima Y, Kawa K, Kyosai T, Sakura T, Jin nai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y.	The role of HLA-match Sakamaki H, Iida H, Kurokawa M, Mi yamura K, Kanamori H, Hara M, Kobayashi N, Morishima Y, Kawa K, Kyosai T, Sakura T, Jin nai I, Takeuchi J, Miyazaki Y, Miyawaki S, Ohnishi K, Naoe T, Kanda Y.	Bone Marrow Transplant.	48(8)	1077-1083	2013
Satoh Y, Yokota T, Sudo T, Kondo M, Lai A, Kincade PW, Koura T, Iidai R, Kokame K, Miyata T, Habuchi Y, Matsui K, Tanaka H, Matsumura I, Oritani K, Kohwi-Shigematsu T, Kanakura Y.	The Satb1 protein directs hematopoietic stem cell differentiation toward lymphoid lineages.	Immunity	38 (6)	1105-1115	2013
Morita Y, Nishimura J, Shimada T, Tanaka H, Serizawa a K, Taniguchi Y, Tsuritani M, Kanakura Y, Matsumura I.	Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.	Int J Hematol	97 (4)	491-497	2013
薄井紀子	成人急性骨髓性白血病の治療	日本内科学会雑誌	第102巻 第7号	1687-1695	2013
薄井紀子	成人再発・治療抵抗性急性白血病への治療方針	臨床腫瘍プラクティス	10巻1号	37-42	2014

Yanada M, Kurosawa S, Yamaguchi T, Uchida N, Miyawaki C, Kanamori H, Usuki K, Kobayashi T, Watanabe M, Nagafuji K, Yano S, Nawa Y, Tomiyama J, Tashiro H, Nakamura Y, Fujisawa S, Kimura F, Emi N, Miura I, Fukuda T.	Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation.	Bone Marrow Transplantation	48	390-39	2013
Shinichi Kako, Hiroki Iwai, Kanamori, Naoko, Kobayashi, Akiko, Shigematsu, Yasuo, Nannya, Mikio, Nakamae, Kazuyuki, Shigeno, Kazumi, Suzuki, Masahiro, Takeuchi, Motohiro, Tsuzuki, Kensuke, Usuki, Kazuo, Hatanaka, Kazue, Ogawa, Kinuko, Mitani, Yuichiro, Nawa, Yoshihiro, Hatta, Ishikazu, Mizuno, Yoshinobu, Kanda.	Outcome after first relapse in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia.	British Journal of Haematology	161	95-103	2013
Ueda Y, Mizutani C, Nannya Y, Kuroki S, Takeuchi J, Teramura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Nesumi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Oga wa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F	Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndrome.	Leuk Lymphoma	54	1450-1458	2013

Fujisawa S, Nakam ae H, Ogura M, Isf hizawa K, Taniwak i M, Utsunomiya A, Matsue K, Takag matsu Y, Usuki K, Tanimoto M, Ishi da Y, Akiyama H, Onishi S.	Efficacy and safety o f dasatinib versus im atinib in Japanese pa tients with newly dia gnosed chronic-phase chronic myeloid leuke mia (CML-CP): Subset analysis of the DASIS ION trial with 2-year follow-up.	Int J Hematol.	99	141-53	2014
臼杵憲祐	急性リンパ性白血病の 治療	日本内科学会雑誌	102	1696-1704.	2013
臼杵憲祐	冷式抗体による自己免 疫性溶血性貧血	内科	112	271-274	2013
臼杵憲祐	再生不良性貧血に対す るエルトロンボパグ	血液フロンティア	23	1448-1452	2013
臼杵憲祐	MDSにおけるG-CSFの使 用法	血液内科	67	313-318	2013
岡田定、東光久、臼 杵憲祐	座談会 非血液専門医が 血液診療にどう関われ ばよいか。	medicina	51	396-405	2014
臼杵憲祐	貧血の誤診	medicina	51	476-479	2014
Experts in Chroni c Myeloid Leukemi a (Matsumura I, Ok nishi K, Ohno R, Takahashi N, Tau chi T, Usuki K, et al)	The price of drugs fo r chronic myeloid leu kemia (CML) is a refl ection of the unsustai nable prices of canc er drugs: from the pe rspective of a large group of CML experts.	Blood	30;121(2):4439-42 2):		2013
Nakamura S, Tan L, Nagata Y, Takeg mura T, Asahina A, Yokota D, Yagy u T, Shibata K, Fuj isawa S, Ohnishi i K.	JmjC-domain containin g histone demethylase 1B-mediated p15(INK4 b) suppression promot es the proliferation of leukemic progenitor cells through modul ation of cell cycle pro gression in acute my eloid leukemia.	Mol Carcinog.	52(1)	57-69	2013

Iriyama N, Asou N, Miyazaki Y, Yamaguchi S, Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Otake S, Hatta Y, Sakamoto H, Aki H, Honda S, Tezuka T, Taniwaki M, Miyawaki S, Ohnishi K, Kobayashi Y, Naoe T.	Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcome.	Ann Hematol.	PMID: 24441947	Epub ahead of print	2014
Nishida Y, Mizutani N, Inoue M, Mori Y, Tamiya-Koizumi K, Takagi A, Kojima T, Suzuki M, Nozawa Y, Minami Y, Ohnishi K, Naoe T, Murate T.	Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell lines.	Biophys Acta.	doi: 10.1016/j.bbapgr.2014.02.004.	Epub ahead of print]	2014
Kihara R, Nagata Y, Kiyoji H, Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Otake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K, Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F, Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S and Naoe T.	Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.	Leukemia		in press	2014
Ono T, Takeshita A, Kishimoto Y, Kiyoji H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa A, Monma F, Otake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; The Japan Adult Leukemia Study Group.	Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.	Cancer Sci	105	97-104	2014

Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriya ma C, Hirose T, Semistry-positive and hirahata-Adachi M, Suzuki Y, Mizu no H, Kiyo i H, Asano N, Nakamura S, Kinoshita T, Naoe T.	De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: Molecular mechanisms and correlation with rituximab sensitivity.	Cancer Sci	105	35-43	2014
Yasuda T, Ueno T, Fukumura K, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyo i H, Naoe T, Mano H.	Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation.	Leukemia	28(2)	426-8	2014
Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H, Okada M, Inoue Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T, Nakaseko C, Ishiguro Y, Shinagawa K, Takeshita A, Miyazaki Y, Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group.	Role of hematopoietic stem cell transplantation for relapsed acute promyelocytic leukemia: a retrospective analysis of JALSG-APL97.	Cancer Sci	104	1339-1345	2013
Yanada M, Ohtake S, Miyawaki S, Saeki H, Kamaki H, Sakura T, Maeda T, Miyamaura K, Asou N, Ohbayashi I, Miyatake J, Takeuchi J, Takahashi M, Dobashi N, Kiyo i H, Miyazaki Y, Emi N, Kobayashi Y, Ohno R, Naoe T; Japan Adult Leukemia Study Group.	The demarcation between younger and older acute myeloid leukemia patients: a pooled analysis of 3 prospective studies.	Cancer	119	3326-3333	2013

Tomita A, Kiyoi H, Naoe T.	Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in acute promyelocytic leukemia.	Int J Hematol	97	717-725	2013
Kiyoi H.	Guest editorial: efficacy of and resistance to molecularly targeted therapy for myeloid malignancies.	Int J Hematol	97	681-682	2013
Atsuta Y, Suzuki R, Yamashita T, Fukukawa T, Miyamura K, Taniguchi S, Iida H, Uchida T, Ikegami K, Takahashi S, Kato K, Asashi S, Nagamura-Tsuchiya T, Morishima Y, Sakamaki H, and Kodera Y.	Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease.	Ann Oncol			in press
Yanada M, Tsuzuki M, Fujita H, Fujimura K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N.	Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.	Blood	121(16)	3095-102	2013
Atsuta Y, Kanda J, Takanashi M, MHLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.	Different effects of MHLA disparity on transplant outcomes after single-unit cord blood transplantation between pediatric and adult patients with leukemia.	Haematologica	98(5)	814-22.	2013
伊藤良和	高齢者急性骨髓性白血病治療としてのgemtuzumab ozogamicin併用化学療法	臨床血液	印刷中		2014

H Kanamori, S Mizuta, S Kako, H Kalogeneic stem cell transplantation	Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation	Bone Marrow Transplantation	48	1513-1518	2013
Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Otake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T.	CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).	Leuk Res	37(9)	1021-1026	2013
Naoe T, Kiyo H.	Genetic mutations of acute myeloid leukemia in the genome era.	Int J Hematol	97(2)	165-174	2013